PVCT · Provectus Biopharmaceuticals, Inc.
$0.06
0.00 (-2.32%)
At close · Aug 26
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$23.33M
Shares
420.28M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.06
Open$0.06
Day$0.06–0.06
52W close$0.04–0.09
Avg vol 30d179K
Short int802K · 0.2% float · 3.8d
Short vol24%
DataJan 2020–Aug 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
−5%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
40%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+11%
trailing
YTD return
+5%
this year
Relative strength
−1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Distributing
-33% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.19% of float · ▲ +0.0% MoM · 3.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
4 holders — near 4-yr low, contrarian setup
Squeeze score
31
low risk · 0–100
Fundamentals
EPS growth
0%
Y/Y
Free cash flow
$-3.4M
Balance sheet
$248.7K
net debt
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
−5%
Bearish
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
40%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Distributing
-33% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.19% of float · ▲ +0.0% MoM · 3.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
4 holders — near 4-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 40%
Range high $0
vs 200-day avg 0%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PVCT
this stock
Provectus Biopharmaceuticals, Inc.
|
$23.33M | +5.2% | -45.5% | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
4
- % held
- 0.0%
- Net QoQ
- -72.6K sh
- Top holder
- HOME FEDERAL BANK OF TENN…
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PVCT | +1.2% | -5.0% | +11.1% | -5.8% | +5.2% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +1.6% | -10.0% | -1.3% | -8.3% | -7.2% |